AstraZeneca (NASDAQ: AZN) has announced an ambitious plan to increase its total revenue to $80 billion by 2030, up from $45.8 billion in 2023. The growth will be driven by expanding its oncology, biopharmaceuticals, and rare disease portfolios, and introducing 20 new medicines by the end of the decade. The company will also invest in transformative technologies and platforms to sustain growth beyond 2030. AstraZeneca aims to achieve a mid-30s percentage core operating margin by 2026 and maintain it post-2026. Analysts have mixed views on the revenue target, with some seeing a 20% upside to the 2030 consensus.